Close
ACHEMA MIDDLE EAST 2026
5th LNP Formulation & Process Development Summit

Press Statements

      Janssen Pierce To Globally Collabrate With Theravance Biopharma For Oral, Pan-Jak Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease

      Drug Development
      The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to...

      Roche’s TECENTRIQ®and Avastin® reduced the risk of disease worsening or death by 26 percent in certain advanced kidney cancer cases

      Clinical Trials
      Roche announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic...

      Shire presentations at EAHAD 2018 demonstrate commitment to studying outcomes in patients with bleeding disorders

      Drug Development
      Shire plc , the global biotechnology leader in rare diseases, today announced the range of real-world and long-term research it will present at the...

      Treatment and Management of Rare Lysosomal Diseases highlighted by shire at Global Conference

      Clinical Trials
      Shire plc  the global biotechnology leader in rare diseases, today announced that it will have 12 presentations, including 11 posters and one oral presentation,...

      Positive Results from the Pivotal Phase III ‘OPTIMISMM’ Study of POMALYST/IMNOVID

      Clinical Trials
      Celgene Corporation announced that the Phase III, randomized, open-label, international clinical study, OPTIMISMM, achieved its primary endpoint, showing a statistically significant and clinically meaningful...

      Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

      Clinical Trials
      Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in a phase 1 study evaluating the safety and...

      Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant – an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine.

      Clinical Trials
      Allergan plc , a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two pivotal phase 3 clinical...

      Subscribe Our Newsletter

      White Papers

      The Future of Digital Health

      Whitepapers 0
      The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

      Five Best Practices to Deliver Exceptional Multichannel Experiences

      Whitepapers 0
      A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

      The Impact and Use of Social Media in Pharmacovigilance

      Whitepapers 0
      Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

      About us

      Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
      comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

      Resources

      Advertise

      Subscribe

      Copyright © Value Media Group 2026. All rights reserved.